Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Fineline Cube Mar 4, 2026
Company Deals

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Fineline Cube Mar 4, 2026
Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Fineline Cube Mar 5, 2026
Company Drug

HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors

Fineline Cube Mar 5, 2026
Company Drug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

Fineline Cube Mar 5, 2026
Company Deals

Apeloa Pharmaceutical Partners with Biocre Tech to Boost Pharmaceutical Innovation

Fineline Cube Sep 27, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a pharmaceutical company based in China, has entered into...

Company Deals

FDA Approves Cobenfy as Novel Schizophrenia Treatment with First-in-Decades Mechanism

Fineline Cube Sep 27, 2024

The U.S. Food and Drug Administration (FDA) has granted official approval to Cobenfy (KarXT, xanomeline...

Policy / Regulatory

Hunan Province Includes Fertility Treatments in Medical Insurance Coverage from October 2024

Fineline Cube Sep 27, 2024

The Hunan Healthcare Security Administration has issued a notification to include specific assisted reproductive medical...

Company Deals

Shanghai Junshi Biosciences Inks Licensing Deal for IAMA-001 Nasal Spray with Nanjing JSIAMA

Fineline Cube Sep 27, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China,...

Company

China’s Pharmaceutical Industry Sees Mixed Results in H1 2024, CAPEM Data Reveals

Fineline Cube Sep 27, 2024

The China Association of Pharmaceutical Enterprises Management (CAPEM) has released a comprehensive set of data...

Policy / Regulatory

Shanghai Medical Procurement Platform Sets Price Cap for Non-Locally Supplied Drugs

Fineline Cube Sep 27, 2024

Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) has issued a notification concerning the online procurement prices...

Company Deals

Pfizer Partners with Shanghai Pharmaceutical for Long-Term Vaccine Collaboration in China

Fineline Cube Sep 27, 2024

Pfizer Inc. (NSE: PFIZER, NYSE: PFE, ETR: PFE), a leading pharmaceutical company in the U.S.,...

Drug

FDA Panel Weighs in on Narrowing Use of PD-1 Inhibitors in Stomach and Esophageal Cancers

Fineline Cube Sep 27, 2024

The U.S. FDA’s Oncologic Drugs Advisory Committee (ODAC) convened on September 26 to scrutinize the...

Company Drug

2seventy bio and BMS Discontinue Phase III Trial for Multiple Myeloma Therapy Abecma

Fineline Cube Sep 26, 2024

2seventy bio Inc. (NASDAQ: TSVT), a U.S.-based biotechnology company partnered with Bristol-Myers Squibb (BMS, NYSE:...

Company Drug

Zelgen Biopharmaceuticals Receives NMPA Approval for ZG005 Clinical Trial in Advanced Solid Tumors

Fineline Cube Sep 26, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company

Johnson & Johnson Reportedly Winding Down Cardiovascular and Metabolic Pharma Unit

Fineline Cube Sep 26, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a healthcare giant in the U.S., is reportedly winding...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for Generic Vizamyl Clinical Trial

Fineline Cube Sep 26, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Medical Device

Sansure Biotech’s HPV Detection Kit Receives NMPA Approval for Comprehensive Screening

Fineline Cube Sep 26, 2024

Sansure Biotech Inc., a molecular diagnostics specialist based in China and listed on the Shanghai...

Company Digital Medical Device

ClouDr Receives NMPA Green Light for ClouDT-01, a Groundbreaking Digital Diabetes Treatment

Fineline Cube Sep 26, 2024

Hangzhou Kang Ming Information Technology Co., Ltd, trading under the banner of “ClouDr” on the...

Company Drug

Sino Biopharmaceutical Receives NMPA Approval for Rivastigmine Patch for Mild-to-Moderate Alzheimer’s

Fineline Cube Sep 26, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced that...

Company Deals

Belief BioMed Partners with Bayer’s AskBio to Explore New Gene Therapies

Fineline Cube Sep 26, 2024

Belief BioMed Inc. (BBM), a Chinese biopharmaceutical company specializing in gene therapy, has announced a...

Company Deals

Shanghai Fosun Pharmaceutical Partners with State-owned Firms to Boost ASEAN Drug Trade

Fineline Cube Sep 26, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company in...

Policy / Regulatory

Beijing Authorities Launch Plan to Streamline Temporary Import of Urgently Needed Medical Drugs and Devices

Fineline Cube Sep 26, 2024

In a joint effort to streamline access to critical medical resources, the Beijing Municipal Medical...

Hospital Policy / Regulatory

Beijing Expands Medical Insurance Coverage to Include Anti-Aquaporin Antibody Testing and Advanced Heart Procedures

Fineline Cube Sep 26, 2024

The Beijing Municipal Medical Insurance Bureau and the Beijing Municipal Human Resources and Social Security...

Company Drug

Innovent Biologics Submits Market Approval Filing for Picankibart in Plaque Psoriasis to China’s CDE

Fineline Cube Sep 26, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has reportedly submitted...

Posts pagination

1 … 256 257 258 … 631

Recent updates

  • HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors
  • AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12
  • China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion
  • AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics
  • Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors

Company Drug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.